Atomoxetine
- Generic Name
- Atomoxetine
- Brand Names
- Strattera
- Drug Type
- Small Molecule
- Chemical Formula
- C17H21NO
- CAS Number
- 83015-26-3
- Unique Ingredient Identifier
- ASW034S0B8
- Background
Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve developmentally inappropriate symptoms associat...
- Indication
Atomoxetine is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adults.
- Associated Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- Associated Therapies
- -
Open-Label Study of the Long Term Tolerability and Safety of Atomoxetine in Children With FASD and ADD/ADHD
- Conditions
- Interventions
- First Posted Date
- 2007-01-04
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- University of Oklahoma
- Target Recruit Count
- 27
- Registration Number
- NCT00418262
- Locations
- 🇺🇸
OU Child Study Center, Oklahoma City, Oklahoma, United States
Comparison of Atomoxetine Versus Placebo in Children and Adolescents With ADHD and Comorbid ODD in Germany
- Conditions
- Interventions
- First Posted Date
- 2006-12-04
- Last Posted Date
- 2010-02-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 181
- Registration Number
- NCT00406354
- Locations
- 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Munchen, Germany
Atomoxetine for Attention Deficit Hyperactivity Disorder in Adolescents With Substance Use Disorder
- Conditions
- Interventions
- First Posted Date
- 2006-11-15
- Last Posted Date
- 2015-07-08
- Lead Sponsor
- Denver Health and Hospital Authority
- Target Recruit Count
- 70
- Registration Number
- NCT00399763
- Locations
- 🇺🇸
Denver Health Medical Center, Denver, Colorado, United States
Efficacy, Tolerability, and Safety of Once-Daily Atomoxetine Hydrochloride Versus Placebo in Russian Children and Adolescents With Attention-Deficit/Hyperactivity Disorder
- Conditions
- First Posted Date
- 2006-10-11
- Last Posted Date
- 2007-06-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 105
- Registration Number
- NCT00386581
- Locations
- 🇷🇺
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Moscow, Russian Federation
Atomoxetine Versus Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents With Autism Spectrum Disorder
- Conditions
- Interventions
- First Posted Date
- 2006-09-26
- Last Posted Date
- 2010-05-11
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 97
- Registration Number
- NCT00380692
- Locations
- 🇳🇱
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Utrecht, Netherlands
Atomoxetine and Huntington's Disease
- Conditions
- Interventions
- First Posted Date
- 2006-08-29
- Last Posted Date
- 2012-12-20
- Lead Sponsor
- University of Iowa
- Target Recruit Count
- 20
- Registration Number
- NCT00368849
- Locations
- 🇺🇸
The University of Iowa, Iowa City, Iowa, United States
Atomoxetine Treatment for ADHD and Marijuana Dependence
- Conditions
- Interventions
- First Posted Date
- 2006-08-04
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 38
- Registration Number
- NCT00360269
- Locations
- 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
Treatment of Prisoners With Attention Deficit Hyperactive Disorder in Trondheim Prison
- Conditions
- First Posted Date
- 2006-07-25
- Last Posted Date
- 2017-04-28
- Lead Sponsor
- Norwegian University of Science and Technology
- Target Recruit Count
- 40
- Registration Number
- NCT00356070
- Locations
- 🇳🇴
St. Olavs Hospital. Departement for forensic psyciatry, Brøset., Trondheim, Norway
Atomoxetine in the Treatment of Binge Eating Disorder
- Conditions
- First Posted Date
- 2006-05-19
- Last Posted Date
- 2011-06-22
- Lead Sponsor
- Lindner Center of HOPE
- Registration Number
- NCT00327834
- Locations
- 🇺🇸
University of Cincinnati Medical Center, Cincinnati, Ohio, United States
Efficacy of Atomoxetine on Psychosocial Function of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)
- Conditions
- Interventions
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2010-01-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 269
- Registration Number
- NCT00320528
- Locations
- 🇮🇹
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Viterbo, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.